Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for military-related posttraumatic stress disorder. For more information, please visit www.thehonorstudy.com or www.clinicaltrials.gov (NCT03062540).

News / Press Releases

: Press Releases

Press Releases

Tonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option

April 13, 2017 • 11:30 AM EDT

Tonix Pharmaceuticals Reports Results from U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting on TNX-102 SL for Posttraumatic Stress Disorder

April 11, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Completes $8 Million Public Offering of Common Stock

April 4, 2017 • 11:30 AM EDT

Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement

April 3, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Prices Public Offering of 1,800,000 Shares of Common Stock

March 30, 2017 • 8:01 AM EDT

Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock

March 29, 2017 • 4:07 PM EDT

Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at The MicroCap Conference

March 29, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Enrolls First Participant in Military-Related PTSD Phase 3 Trial of FDA Breakthrough Therapy-Designated TNX-102 SL

March 28, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split

March 16, 2017 • 1:00 PM EDT

Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program at Oppenheimer’s 27th Annual Healthcare Conference

March 15, 2017 • 7:00 AM EDT

« Previous
1
2
3
4
5
6
7
8
9
10
...21
Next »

Show All

News / Press Releases : Press Releases